The upcoming 5th edition of the World Health Organization (WHO) Classification of
Haematolymphoid Tumours is part of an effort to hierarchically catalogue human cancers …

The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over
the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy …

Importance Measurable residual disease (MRD) refers to neoplastic cells that cannot be
detected by standard cytomorphologic analysis. In patients with acute myeloid leukemia …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] …

With the improving knowledge of CML and its management, the goals of therapy need to be
revisited to ensure an optimal use of the BCR:: ABL1 TKIs in the frontline and later-line …

The first wave of genetically targeted therapies for cancer focused on drugging gene
products that are recurrently mutated in specific cancer types. However, mutational analysis …

Chronic myeloid leukemia (CML), caused by constitutively active BCR-ABL1 fusion tyrosine
kinase, has served as a paradigm for successful application of molecularly targeted cancer …

To a large extent, cancer conforms to evolutionary rules defined by the rates at which clones
mutate, adapt and grow. Next-generation sequencing has provided a snapshot of the …

Receptor tyrosine kinases (RTKs) are key regulatory signaling proteins governing cancer
cell growth and metastasis. During the last two decades, several molecules targeting RTKs …

Summary Background Tyrosine kinase inhibitors (TKIs) have improved the survival of
patients with chronic myeloid leukaemia. Many patients have deep molecular responses, a …